{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:38:55Z","timestamp":1793777935938,"version":"4.6.1"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine & Growth Factor Reviews"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.cytogfr.2020.06.006","type":"journal-article","created":{"date-parts":[[2020,6,7]],"date-time":"2020-06-07T11:02:56Z","timestamp":1591527776000},"page":"70-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["IL-36 in chronic inflammation and cancer"],"prefix":"10.1016","volume":"55","author":[{"given":"Markus F.","family":"Neurath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cytogfr.2020.06.006_bib0005","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41584-019-0277-8","article-title":"The IL-1 family of cytokines and receptors in rheumatic diseases","volume":"15","author":"Dinarello","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000481210","article-title":"E3 ubiquitin ligase RNF125 activates interleukin-36 receptor signaling and contributes to its turnover","volume":"10","author":"Saha","year":"2018","journal-title":"J. Innate Immun."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cyto.2014.03.002","article-title":"Long-range DNA interactions at the IL-1\/IL-36\/IL-37 gene cluster (2q13) are induced by activation of monocytes","volume":"68","author":"Sharaf","year":"2014","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/2211-5463.12044","article-title":"Production of biologically active IL-36 family cytokines through insertion of N-terminal caspase cleavage motifs","volume":"6","author":"Clancy","year":"2016","journal-title":"FEBS Open Bio"},{"issue":"8","key":"10.1016\/j.cytogfr.2020.06.006_bib0025","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1073\/pnas.1121534109","article-title":"IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist","volume":"109","author":"van de Veerdonk","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/039463201302600103","article-title":"IL-36 receptor antagonist with special emphasis on IL-38","volume":"26","author":"Shaik","year":"2013","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1074\/jbc.M117.805739","article-title":"Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation","volume":"293","author":"Zhou","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"49","key":"10.1016\/j.cytogfr.2020.06.006_bib0040","doi-asserted-by":"crossref","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0045","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4049\/jimmunol.1400538","article-title":"Molecular determinants of agonist and antagonist signaling through the IL-36 receptor","volume":"193","author":"Gunther","year":"2014","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0050","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1189\/jlb.3RI1014-495R","article-title":"Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions","volume":"97","author":"Gabay","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0055","doi-asserted-by":"crossref","first-page":"24880","DOI":"10.1038\/srep24880","article-title":"Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist","volume":"6","author":"Macleod","year":"2016","journal-title":"Sci. Rep."},{"issue":"39","key":"10.1016\/j.cytogfr.2020.06.006_bib0060","doi-asserted-by":"crossref","first-page":"23997","DOI":"10.1074\/jbc.M115.653378","article-title":"Signal transduction and intracellular trafficking by the interleukin 36 receptor","volume":"290","author":"Saha","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"32","key":"10.1016\/j.cytogfr.2020.06.006_bib0065","doi-asserted-by":"crossref","first-page":"16597","DOI":"10.1074\/jbc.M116.723064","article-title":"Structural and functional attributes of the Interleukin-36 receptor","volume":"291","author":"Yi","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.cytogfr.2020.06.006_bib0070","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41419-018-0385-4","article-title":"Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases","volume":"9","author":"Sullivan","year":"2018","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0075","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.4110\/in.2018.18.e27","article-title":"Damage-associated molecular patterns in inflammatory diseases","volume":"18","author":"Roh","year":"2018","journal-title":"Immune Netw."},{"issue":"5","key":"10.1016\/j.cytogfr.2020.06.006_bib0080","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/2211-5463.12406","article-title":"Identification of small-molecule elastase inhibitors as antagonists of IL-36 cytokine activation","volume":"8","author":"Sullivan","year":"2018","journal-title":"FEBS Open Bio"},{"issue":"11","key":"10.1016\/j.cytogfr.2020.06.006_bib0085","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.celrep.2018.02.062","article-title":"Extracellular neutrophil proteases are efficient regulators of IL-1, IL-33, and IL-36 cytokine activity but poor effectors of microbial killing","volume":"22","author":"Clancy","year":"2018","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0090","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0095","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cyto.2016.05.012","article-title":"Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines","volume":"84","author":"Dietrich","year":"2016","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0100","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1053\/j.gastro.2018.11.029","article-title":"Inhibiting interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation","volume":"156","author":"Scheibe","year":"2019","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.cytogfr.2020.06.006_bib0105","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1182\/blood-2011-05-356873","article-title":"IL-36R ligands are potent regulators of dendritic and T cells","volume":"118","author":"Vigne","year":"2011","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.cytogfr.2020.06.006_bib0110","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood-2012-06-439026","article-title":"IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells","volume":"120","author":"Vigne","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cytogfr.2020.06.006_bib0115","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/gutjnl-2015-310374","article-title":"IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo","volume":"66","author":"Scheibe","year":"2017","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.cytogfr.2020.06.006_bib0120","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fimmu.2018.00080","article-title":"RNA-seq analysis of IL-1B and IL-36 responses in epidermal keratinocytes identifies a shared MyD88-dependent gene signature","volume":"9","author":"Swindell","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jdermsci.2012.07.010","article-title":"Interleukin-36 cytokines enhance the production of host defense peptides psoriasin and LL-37 by human keratinocytes through activation of MAPKs and NF-kappaB","volume":"68","author":"Nguyen","year":"2012","journal-title":"J. Dermatol. Sci."},{"issue":"40","key":"10.1016\/j.cytogfr.2020.06.006_bib0135","doi-asserted-by":"crossref","first-page":"10088","DOI":"10.1073\/pnas.1801377115","article-title":"IkappaBzeta is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes","volume":"115","author":"Muller","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.cytogfr.2020.06.006_bib0140","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.4049\/jimmunol.1301481","article-title":"IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin","volume":"192","author":"Foster","year":"2014","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2020.06.006_bib0145","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jid.2018.12.003","article-title":"IL-36 signaling is essential for psoriatic inflammation through the augmentation of innate immune responses","volume":"139","author":"Ohko","year":"2019","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0150","doi-asserted-by":"crossref","first-page":"15631","DOI":"10.1038\/s41598-017-15892-7","article-title":"The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function","volume":"7","author":"Pfaff","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0155","doi-asserted-by":"crossref","first-page":"e0222969","DOI":"10.1371\/journal.pone.0222969","article-title":"Interleukin (IL)-17\/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses","volume":"15","author":"Mercurio","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.cytogfr.2020.06.006_bib0160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00403-017-1769-5","article-title":"IL-36 cytokines are increased in acne and hidradenitis suppurativa","volume":"309","author":"Di Caprio","year":"2017","journal-title":"Arch. Dermatol. Res."},{"issue":"12","key":"10.1016\/j.cytogfr.2020.06.006_bib0165","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/jdv.14389","article-title":"Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa","volume":"31","author":"Thomi","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.cytogfr.2020.06.006_bib0170","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.16019","article-title":"Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop","volume":"178","author":"Hessam","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0175","article-title":"Upregulation of IL-36 cytokines in folliculitis and eosinophilic pustular folliculitis","author":"Sato","year":"2019","journal-title":"Australas. J. Dermatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0180","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jid.2018.10.023","article-title":"Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis","volume":"139","author":"Meier-Schiesser","year":"2019","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0185","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1684\/ejd.2015.2694","article-title":"First case of acute generalized exanthematous pustulosis caused by pitavastatin: possible pathogenetic role of IL-36","volume":"26","author":"Saito-Sasaki","year":"2016","journal-title":"Eur. J. Dermatol."},{"issue":"5","key":"10.1016\/j.cytogfr.2020.06.006_bib0190","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.chom.2017.10.006","article-title":"Staphylococcus aureus epicutaneous exposure drives skin inflammation via IL-36-mediated T cell responses","volume":"22","author":"Liu","year":"2017","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0195","first-page":"97","article-title":"Current developments in the immunology of psoriasis","volume":"93","author":"Gran","year":"2020","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PTT.S98893","article-title":"Targeting IL-23 in psoriasis: current perspectives","volume":"8","author":"Fotiadou","year":"2018","journal-title":"Psoriasis"},{"issue":"10","key":"10.1016\/j.cytogfr.2020.06.006_bib0205","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the Interleukin-36 pathway for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0210","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.cytogfr.2020.06.006_bib0215","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/PTT.S190507","article-title":"Increased dermal expression of chromatin-associated protein HMGB1 and concomitant T-cell expression of the DNA RAGE in patients with psoriasis vulgaris","volume":"9","author":"Strohbuecker","year":"2019","journal-title":"Psoriasis"},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0225","first-page":"179","article-title":"Evaluating serum levels of IL-33, IL-36, IL-37 and gene expression of IL-37 in patients with psoriasis vulgaris","volume":"17","author":"Sehat","year":"2018","journal-title":"Iran. J. Allergy Asthma Immunol."},{"issue":"13","key":"10.1016\/j.cytogfr.2020.06.006_bib0230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133318","article-title":"The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis","volume":"20","author":"Madonna","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0235","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdermsci.2015.08.002","article-title":"Expression of IL-36 family cytokines and IL-37 but not IL-38 is altered in psoriatic skin","volume":"80","author":"Keermann","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0240","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12864-015-1508-2","article-title":"Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN","volume":"16","author":"Keermann","year":"2015","journal-title":"BMC Genomics"},{"issue":"11","key":"10.1016\/j.cytogfr.2020.06.006_bib0245","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jid.2016.06.618","article-title":"AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production","volume":"136","author":"Mahil","year":"2016","journal-title":"J. Invest. Dermatol."},{"issue":"411","key":"10.1016\/j.cytogfr.2020.06.006_bib0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2514","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","volume":"9","author":"Mahil","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0255","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s11596-013-1164-1","article-title":"IL-36 cytokine expression and its relationship with p38 MAPK and NF-kappaB pathways in psoriasis vulgaris skin lesions","volume":"33","author":"He","year":"2013","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0260","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12969-019-0338-1","article-title":"Scoping review of biological treatment of deficiency of interleukin-36 receptor antagonist (DITRA) in children and adolescents","volume":"17","author":"Hospach","year":"2019","journal-title":"Pediatr. Rheumatol. Online J."},{"issue":"3","key":"10.1016\/j.cytogfr.2020.06.006_bib0265","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10875-019-00622-7","article-title":"Interleukin-36 receptor antagonist deficiency (DITRA) with a novel IL36RN homozygous mutation c.200G & t (P.Cys67Phe) in a young Colombian woman","volume":"39","author":"Zea-Vera","year":"2019","journal-title":"J. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdcr.2014.12.007","article-title":"Generalized pustular psoriasis with a novel mutation of interleukin-36 receptor antagonist, responding to methotrexate","volume":"1","author":"Teoh","year":"2015","journal-title":"JAAD Case Rep."},{"issue":"6","key":"10.1016\/j.cytogfr.2020.06.006_bib0275","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/bjd.13590","article-title":"Pustular psoriasis-like lesions associated with hereditary lactate dehydrogenase M subunit deficiency without interleukin-36 receptor antagonist mutation: long-term follow-up of two cases","volume":"172","author":"Ito","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"10.1016\/j.cytogfr.2020.06.006_bib0280","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1111\/jdv.12590","article-title":"Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist","volume":"29","author":"Sugiura","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"12","key":"10.1016\/j.cytogfr.2020.06.006_bib0285","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/jdv.12383","article-title":"Generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist successfully treated with granulocyte and monocyte adsorption apheresis","volume":"28","author":"Sugiura","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"11","key":"10.1016\/j.cytogfr.2020.06.006_bib0290","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.cytogfr.2020.06.006_bib0295","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0300","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1111\/bjd.16063","article-title":"Dynamics of plasma cytokines in a patient with deficiency of interleukin-36 receptor antagonist successfully treated with anakinra","volume":"178","author":"Podlipnik","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0305","doi-asserted-by":"crossref","first-page":"451","DOI":"10.5021\/ad.2016.28.4.451","article-title":"Immunohistochemical comparison of IL-36 and the IL-23\/Th17 axis of generalized pustular psoriasis and acute generalized exanthematous pustulosis","volume":"28","author":"Song","year":"2016","journal-title":"Ann. Dermatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0310","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2020.06.006_bib0315","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/exd.13387","article-title":"Mutation in IL36RN impairs the processing and regulatory function of the interleukin-36-receptor antagonist and is associated with DITRA syndrome","volume":"28","author":"Bal","year":"2019","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0320","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamadermatol.2016.3490","article-title":"Response to interleukin (IL)-17 inhibition in an adolescent with severe manifestations of IL-36 receptor antagonist deficiency (DITRA)","volume":"153","author":"Cordoro","year":"2017","journal-title":"JAMA Dermatol."},{"issue":"6","key":"10.1016\/j.cytogfr.2020.06.006_bib0325","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jid.2017.12.024","article-title":"Unopposed IL-36 activity promotes clonal CD4(+) T-cell responses with IL-17A production in generalized pustular psoriasis","volume":"138","author":"Arakawa","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0330","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jdcr.2017.08.019","article-title":"Juvenile interleukin-36 receptor antagonist deficiency (DITRA) with c.80T&C (p.Leu27Pro) mutation successfully treated with etanercept and acitretin","volume":"4","author":"Cuperus","year":"2018","journal-title":"JAAD Case Rep."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0335","doi-asserted-by":"crossref","first-page":"e1043","DOI":"10.1542\/peds.2012-3935","article-title":"First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra","volume":"132","author":"Rossi-Semerano","year":"2013","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.cytogfr.2020.06.006_bib0340","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1111\/1346-8138.14330","article-title":"Deficiency of the interleukin-36 receptor antagonist dramatically improved by secukinumab","volume":"45","author":"Kinoshita","year":"2018","journal-title":"J. Dermatol."},{"issue":"5","key":"10.1016\/j.cytogfr.2020.06.006_bib0345","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/rheumatology\/kex510","article-title":"Successful use of secukinumab in a 4-year-old patient with deficiency of interleukin-36 antagonist","volume":"57","author":"Kostner","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.cytogfr.2020.06.006_bib0350","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/jamadermatol.2016.5705","article-title":"Secukinumab for the treatment of deficiency of interleukin 36 receptor antagonist in an adolescent","volume":"153","author":"Molho-Pessach","year":"2017","journal-title":"JAMA Dermatol."},{"issue":"12","key":"10.1016\/j.cytogfr.2020.06.006_bib0355","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1136\/annrheumdis-2017-212793","article-title":"Standard dose of Ustekinumab for childhood-onset deficiency of interleukin-36 receptor antagonist","volume":"77","author":"Cherqaoui","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.cytogfr.2020.06.006_bib0360","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2017-211805","article-title":"High-dose ustekinumab for severe childhood deficiency of interleukin-36 receptor antagonist (DITRA)","volume":"77","author":"Bonekamp","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.cytogfr.2020.06.006_bib0365","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000688","article-title":"IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis","volume":"3","author":"Goldstein","year":"2020","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0370","doi-asserted-by":"crossref","first-page":"6756138","DOI":"10.1155\/2016\/6756138","article-title":"Imiquimod treatment causes systemic disease in mice resembling generalized pustular psoriasis in an IL-1 and IL-36 dependent manner","volume":"2016","author":"Alvarez","year":"2016","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.10.026","article-title":"Transgenic kallikrein 14 mice display major hair shaft defects associated with desmoglein 3 and 4 degradation, abnormal epidermal differentiation, and IL-36 signature","author":"Gouin","year":"2020","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0380","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123390","article-title":"Disrupting the IL-36 and IL-23\/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis","volume":"4","author":"German","year":"2019","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0385","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.coph.2012.02.009","article-title":"IL-36 in psoriasis","volume":"12","author":"Towne","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0390","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jconrel.2016.05.017","article-title":"Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment","volume":"246","author":"Boakye","year":"2017","journal-title":"J. Controlled Release"},{"issue":"6","key":"10.1016\/j.cytogfr.2020.06.006_bib0395","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jid.2017.12.033","article-title":"Regnase-1, an immunomodulator, limits the IL-36\/IL-36R autostimulatory loop in keratinocytes to suppress skin inflammation","volume":"138","author":"Takaishi","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"11","key":"10.1016\/j.cytogfr.2020.06.006_bib0400","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.cytogfr.2020.06.006_bib0405","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/cmi.2016.70","article-title":"Regnase-1, a rapid response ribonuclease regulating inflammation and stress responses","volume":"14","author":"Mao","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0410","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3389\/fimmu.2019.00746","article-title":"Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4\/IL-36R crosstalk","volume":"10","author":"Shao","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0415","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.intimp.2019.03.016","article-title":"Novel inflammatory cytokines (IL-36, 37, 38) in the aqueous humor from patients with chronic primary angle closure glaucoma","volume":"71","author":"Zhang","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0420","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/s41598-018-19476-x","article-title":"IL-36\/LXR axis modulates cholesterol metabolism and immune defense to Mycobacterium tuberculosis","volume":"8","author":"Ahsan","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.cytogfr.2020.06.006_bib0425","doi-asserted-by":"crossref","first-page":"e0126058","DOI":"10.1371\/journal.pone.0126058","article-title":"Limited contribution of IL-36 versus IL-1 and TNF pathways in host response to mycobacterial infection","volume":"10","author":"Segueni","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0430","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00583-18","article-title":"Overlapping roles for Interleukin-36 cytokines in protective host defense against murine Legionella pneumophila pneumonia","volume":"87","author":"Nanjo","year":"2019","journal-title":"Infect. Immun."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0435","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12879-016-1555-6","article-title":"Increased concentrations of soluble B7-H3 and interleukin 36 in bronchoalveolar lavage fluid of children with Mycoplasma pneumoniae pneumonia","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0440","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fimmu.2016.00376","article-title":"Estrous cycle and gestational age-dependent expression of members of the Interleukin-36 subfamily in a semi-allogeneic model of infected and non-infected murine pregnancy","volume":"7","author":"Murrieta-Coxca","year":"2016","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0445","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4049\/jimmunol.1800515","article-title":"IL-36 and IL-1\/IL-17 drive immunity to oral candidiasis via parallel mechanisms","volume":"201","author":"Verma","year":"2018","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0450","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/eji.201242711","article-title":"The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses","volume":"43","author":"Gresnigt","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0455","article-title":"Designed DNA-encoded IL-36 gamma acts as a potent molecular adjuvant enhancing zika synthetic DNA vaccine-induced immunity and protection in a lethal challenge model","volume":"7","author":"Louis","year":"2019","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.cytogfr.2020.06.006_bib0460","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/glia.23552","article-title":"Spinal IL-36gamma\/IL-36R participates in the maintenance of chronic inflammatory pain through astroglial JNK pathway","volume":"67","author":"Li","year":"2019","journal-title":"Glia"},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0465","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00383-016-4011-1","article-title":"Altered expression of IL36gamma and IL36 receptor (IL1RL2) in the colon of patients with Hirschsprung\u2019s disease","volume":"33","author":"Tomuschat","year":"2017","journal-title":"Pediatr. Surg. Int."},{"issue":"3","key":"10.1016\/j.cytogfr.2020.06.006_bib0470","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.imbio.2019.02.008","article-title":"Interleukin-36 alpha levels are elevated in the serum and cerebrospinal fluid of patients with neuromyelitis optica spectrum disorder and correlate with disease activity","volume":"224","author":"Song","year":"2019","journal-title":"Immunobiology"},{"issue":"5","key":"10.1016\/j.cytogfr.2020.06.006_bib0475","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/15321819.2018.1520128","article-title":"Serum level of interleukin 36 in patients with multiple sclerosis","volume":"39","author":"Alsahebfosoul","year":"2018","journal-title":"J. Immunoassay Immunochem."},{"issue":"7","key":"10.1016\/j.cytogfr.2020.06.006_bib0480","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1681\/ASN.2016080840","article-title":"IL-36 signaling facilitates activation of the NLRP3 inflammasome and IL-23\/IL-17 axis in renal inflammation and fibrosis","volume":"28","author":"Chi","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.cytogfr.2020.06.006_bib0485","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/2211-5463.12845","article-title":"Interleukin-36alpha as a potential biomarker for renal tubular damage induced by dietary phosphate load","volume":"10","author":"Hirano","year":"2020","journal-title":"FEBS Open Bio"},{"issue":"3","key":"10.1016\/j.cytogfr.2020.06.006_bib0490","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.kint.2017.09.017","article-title":"Knockout of the interleukin-36 receptor protects against renal ischemia-reperfusion injury by reduction of proinflammatory cytokines","volume":"93","author":"Nishikawa","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0495","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1038\/srep08521","article-title":"Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury","volume":"5","author":"Scheiermann","year":"2015","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.cytogfr.2020.06.006_bib0500","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.4049\/jimmunol.1600700","article-title":"IL-36-induced toxicity in neonatal mice involves TNF-alpha production by liver myeloid cells","volume":"197","author":"Palomo","year":"2016","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0505","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jbmr.2985","article-title":"IL-36 induces bisphosphonate-related osteonecrosis of the jaw-like lesions in mice by inhibiting TGF-beta-Mediated collagen expression","volume":"32","author":"Kim","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"491","key":"10.1016\/j.cytogfr.2020.06.006_bib0510","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2585","article-title":"TGF-beta type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis","volume":"11","author":"Li","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.cytogfr.2020.06.006_bib0515","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrrheum.2014.156","article-title":"Inflammation: IL-36 has proinflammatory effects in skin but not in joints","volume":"10","author":"Dietrich","year":"2014","journal-title":"Nature Rev. Rheumatol."},{"issue":"12","key":"10.1016\/j.cytogfr.2020.06.006_bib0520","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/eji.201646788","article-title":"Interleukin-36 receptor mediates the crosstalk between plasma cells and synovial fibroblasts","volume":"47","author":"Schmitt","year":"2017","journal-title":"Eur. J. Immunol."},{"issue":"8","key":"10.1016\/j.cytogfr.2020.06.006_bib0525","doi-asserted-by":"crossref","first-page":"e101954","DOI":"10.1371\/journal.pone.0101954","article-title":"Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis","volume":"9","author":"Derer","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0530","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/ar4192","article-title":"The severity of experimental arthritis is independent of IL-36 receptor signaling","volume":"15","author":"Lamacchia","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.cytogfr.2020.06.006_bib0535","doi-asserted-by":"crossref","first-page":"19588","DOI":"10.3390\/molecules201019588","article-title":"Elevated expression and pro-inflammatory activity of IL-36 in patients with systemic lupus erythematosus","volume":"20","author":"Chu","year":"2015","journal-title":"Molecules"},{"issue":"18","key":"10.1016\/j.cytogfr.2020.06.006_bib0540","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.cytogfr.2020.06.006_bib0545","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease","volume":"20","author":"Neurath","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0550","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5140691","article-title":"Differential expression of IL-36 family members and IL-38 by immune and nonimmune cells in patients with active inflammatory bowel disease","volume":"2018","author":"Fonseca-Camarillo","year":"2018","journal-title":"Biomed Res. Int."},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0555","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MIB.0000000000000654","article-title":"Increased expression of Interleukin-36, a member of the Interleukin-1 cytokine family, in inflammatory bowel disease","volume":"22","author":"Nishida","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0560","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cyto.2016.05.023","article-title":"IL-36 receptor is expressed by human blood and intestinal T lymphocytes and is dose-dependently activated via IL-36beta and induces CD4+ lymphocyte proliferation","volume":"85","author":"Penha","year":"2016","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0565","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4049\/jimmunol.1501312","article-title":"Cutting edge: IL-36 receptor promotes resolution of intestinal damage","volume":"196","author":"Medina-Contreras","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0570","doi-asserted-by":"crossref","first-page":"154798","DOI":"10.1016\/j.cyto.2019.154798","article-title":"Increased expression of interleukin 36 in chronic rhinosinusitis and its contribution to chemokine secretion and increased epithelial permeability","volume":"125","author":"Joo","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0575","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cyto.2017.08.022","article-title":"IL-36 induces cytokine IL-6 and chemokine CXCL8 expression in human lung tissue cells: implications for pulmonary inflammatory responses","volume":"99","author":"Zhang","year":"2017","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.cytogfr.2020.06.006_bib0580","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1945892418762844","article-title":"Interleukin (IL) 36 gamma induces mucin 5AC, oligomeric mucus\/gel-forming expression via IL-36 receptor-extracellular signal regulated kinase 1 and 2, and p38-nuclear factor kappa-light-chain-enhancer of activated B cells in human airway epithelial cells","volume":"32","author":"Bae","year":"2018","journal-title":"Am. J. Rhinol. Allergy"},{"issue":"11","key":"10.1016\/j.cytogfr.2020.06.006_bib0585","doi-asserted-by":"crossref","first-page":"e1006737","DOI":"10.1371\/journal.ppat.1006737","article-title":"Interleukin-36gamma and IL-36 receptor signaling mediate impaired host immunity and lung injury in cytotoxic Pseudomonas aeruginosa pulmonary infection: role of prostaglandin E2","volume":"13","author":"Aoyagi","year":"2017","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0590","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/mi.2016.107","article-title":"IL-36 receptor deletion attenuates lung injury and decreases mortality in murine influenza pneumonia","volume":"10","author":"Aoyagi","year":"2017","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.cytogfr.2020.06.006_bib0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106200","article-title":"Interleukin-36 receptor antagonist alleviates airway inflammation in asthma via inhibiting the activation of Interleukin-36 pathway","volume":"81","author":"Liu","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0600","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4049\/jimmunol.1501217","article-title":"Costimulation endows immunotherapeutic CD8 T cells with IL-36 responsiveness during aerobic glycolysis","volume":"196","author":"Tsurutani","year":"2016","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0605","first-page":"197","article-title":"The effect of interleukin 36 gene therapy in the regression of tumor","volume":"7","author":"Solahaye-Kahnamouii","year":"2014","journal-title":"Iran. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.cytogfr.2020.06.006_bib0610","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12885-020-6587-z","article-title":"IL-36 s in the colorectal cancer: is interleukin 36 good or bad for the development of colorectal cancer?","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Cancer"},{"issue":"477","key":"10.1016\/j.cytogfr.2020.06.006_bib0615","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36gamma, and OX40L mRNAs","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2020.06.006_bib0620","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/13543776.2014.881473","article-title":"Anti-IL-36R antibodies, potentially useful for the treatment of psoriasis: a patent evaluation of WO2013074569","volume":"24","author":"Wolf","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"issue":"5","key":"10.1016\/j.cytogfr.2020.06.006_bib0625","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1080\/19420862.2019.1615345","article-title":"Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5)","volume":"11","author":"Ahlberg","year":"2019","journal-title":"mAbs"},{"issue":"7","key":"10.1016\/j.cytogfr.2020.06.006_bib0630","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/19420862.2017.1353853","article-title":"Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies","volume":"9","author":"Ganesan","year":"2017","journal-title":"mAbs"}],"container-title":["Cytokine & Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610120301027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610120301027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:57:05Z","timestamp":1761217025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610120301027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":126,"alternative-id":["S1359610120301027"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2020.06.006","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-36 in chronic inflammation and cancer","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2020.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}